January Therapeutics Names Scientific Advisory Board


January Therapeutics, an emerging oncology research and development company, announces a panel of renown scientific advisors

January Therapeutics, Inc., was formed around a proprietary therapeutic platform dubbed the Chemistry-enabled Albumin Nanoparticle (CAN) Platform. The company recently named a number of experts to provide advice on the development of the various compounds in the January pipeline.

"We have assembled a distinctive group of respected leaders in the fields of cancer research and drug development," said Neil Raheja, Ph.D., January's CEO & CSO, "and we look forward to collaborating with them in the development of our promising pipeline of therapeutics." 

The scientific advisors include:

  • Gary Schwartz, MD - Division Chief, Hematology/ Oncology and Deputy Director Columbia University Irving Cancer Center
  • David Carbone, MD, PhD - Director, James Thoracic Center at Ohio State University
  • John Nuss, PhD - Inventor of Cabozantinib, Cobimetinib, and Esazerenone. Previously UC Riverside, Chiron, Exelixis
  • Bruce Roth, PhD - Inventor of Lipitor.  Previously Parke-Davis, Warner-Lambert, Pfizer, Genentech